Eterna Therapeutics Enters Into Option And License Agreement With Lineage Cell Therapeutics To Develop Hypoimmune Pluripotent Cell Lines For Multiple Neurology Indications
Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna"), a preclinical-stage biotechnology company committed to realizing the potential of mRNA cell engineering to provide patients with transformational